June 21, 2023 — Royal Philips, a global leader in health technology, announced it has teamed up with BIOTRONIK (Lake Oswego, Oregon, United States) a leading global medical device company with products and services that improve the lives of patients suffering from cardiovascular and endovascular diseases, to expand the range of cardiovascular devices available for Philips SymphonySuite customers.
Philips SymphonySuite is the market-leading solution for opening and expanding cardiovascular office-based labs (OBLs) and ambulatory surgery centers (ASCs), and includes a full range of high-performing, highly specialized equipment and devices, personalized services, financing options, site-planning, ongoing operational support and device programs.
With more procedures moving to out-of-hospital care settings such as OBLs and ASCs, the combination of Philips SymphonySuite and the full range of BIOTRONIK’s cardiac rhythm management, cardiovascular intervention, and peripheral vascular intervention product portfolio provides more options to individualize patient care and create treatment strategies for low-risk cardiac procedures performed in these settings.
Healthcare providers continue to support this shift of care settings due to patient demand, improvements in medical technology, and operational benefits. Out-of-hospital care settings increase access to care and allow for a more personalized patient experience with a lower risk of hospital-acquired infections for patients. In general, procedures performed in out-of-hospital settings have lower overhead and capital costs – and these savings help drive lower costs for patients.
“Philips is committed to expanding access to care through its innovative solutions and BIOTRONIK’s alliance adds additional devices, including a cardiac rhythm management portfolio, to SymphonySuite,” said Chris DeCarolis, Head of Procedural Solutions for Image Guided Therapy at Philips. “We will continue to evolve to stay ahead of the needs of physicians and patients and provide cardiovascular equipment, devices and services in out-of-hospital settings while reducing cost pressures via innovative business models.”
Atul Suri, Vice President of Commercial Excellence at BIOTRONIK, added: “Through BIOTRONIK’s innovative cardiovascular technologies, we’re committed to partnering with outpatient sites of service. Aligning with Philips will allow us to bring greater value to our outpatient customers, particularly those with capital equipment needs for ASC and OBL facilities.”
For more information: www.philips.com
July 18, 2024 
